Amneal Pharmaceuticals (NASDAQ:AMRX) reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjust
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on ...
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing earnings results this Thursday before market hours. Here’s what to expect. Amn...
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...
Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The...
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AM...
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches.
Speaking at a Gol
What Happened? Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 5.7% in the afternoon session after the U.S. Food and Drug Admini...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%. ...
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Friday before market hours. Here’s what you need to know. Amneal ...
What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...
